Trial Profile
Pilot trial of two dose levels of Thymoglobulin [antithymocyte globulin] as part of a myeloablative-conditioning for a HLA [human leukocyte antigen] identical matched related donor (MRD) stem cell transplant with cyclosporine (CsA) [ciclosporin] as posttransplant graft vs host disease (GvHD) prophylaxis
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Ciclosporin
- Indications Acute myeloid leukaemia; Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Oct 2005 New trial record.